DYADIC INTERNATIONAL INC
DYAI evidence brief
What we can confirm
- BioSniper Score:
- 2.5 / 10
- Market Cap:
- $18.6M
What it means
What to watch
Prepared research question
What matters most for DYAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DYAI
DYADIC International Inc. (DYAI) is a biotechnology company developing microbial protein production platforms, primarily the C1 and Dapibus™ systems, for use in human and animal biopharmaceuticals and non-therapeutic products, while currently generating minimal revenue and facing significant financial challenges.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$18.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
DYADIC International Inc. (DYAI) is a biotechnology company developing microbial protein production platforms, primarily the C1 and Dapibus™ systems, for use in human and animal biopharmaceuticals and non-therapeutic products, while currently generating minimal revenue and facing significant financial challenges.
- Cash & equivalents of $1.4M as of 2026-06-30 [sec]
- Total revenue of $1.0M and net income of -$2.1M as of 2026-06-30 [sec]
- Shareholders' equity of -$2.4M as of 2026-06-30 [sec]
- C1 platform addresses key bottlenecks in biologics manufacturing by reducing cost, shortening development cycles, and enabling higher yields [sec_mda · as of 2025-11-12]
- Company expects existing cash, cash equivalents, restricted cash and investment securities totaling approximately $6.6 million as of March 31, 2026, to be sufficient for at least the next twelve months [sec_mda · as of 2026-05-13]
What works
- C1 platform is positioned as a competitive alternative to CHO, yeast, and insect cell systems for biologics manufacturing, reducing cost and development cycles [sec_mda · as of 2025-11-12]
- Dyadic advances selected biopharmaceutical programs through fully funded collaborations with global health organizations, government agencies, and research institutions [sec_mda · as of 2026-03-25]
- The C1 platform continues to attract interest from pharmaceutical companies, CDMOs, academic institutions, and government agencies for applications including recombinant vaccines and therapeutics [sec_mda · as of 2026-03-25]
What to weigh
- The company has negative net cash flows from operating activities and expects net losses over the next several years, adversely affecting working capital and financial condition [sec_mda · as of 2026-03-25]
- Management is required to evaluate whether conditions raise substantial doubt about the company's ability to continue as a going concern for at least 12 months [sec_mda · as of 2026-05-13]
- The company may need substantial additional capital in the future, and there is no guarantee that strategic or financing opportunities will be available [sec_mda · as of 2026-03-25]
- Clinical development setbacks are possible even after promising early results, and there is no assurance of regulatory approval for any product candidates [sec_mda · as of 2026-03-25]
From the filings
Quoted directly from source documents.
Cash position as of March 31, 2026
“The Company expects its existing cash, cash equivalents, restricted cash and its investment securities, including accrued interest, totaling approximately $6.6 million as of March 31, 2026”
SEC MD&A · May 13, 2026
C1 platform advantages
“C1 addresses key bottlenecks in biologics manufacturing--reducing cost, shortening development cycles, and enabling higher yields--positioning it as a competitive alternative to CHO, yeast, and insect cell systems.”
SEC MD&A · November 12, 2025
Going concern evaluation requirement
“management is required to evaluate whether there are conditions and events, considered in the aggregate that raise substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the issuance date of the Company's financial statements.”
SEC MD&A · May 13, 2026
Net losses expected
“The net losses we anticipate incurring over the next several years will have an adverse effect on our working capital, financial condition, results of operations and prospects.”
SEC MD&A · March 25, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management must evaluate if conditions raise substantial doubt about the company's ability to continue as a going concern for 12 months [sec_mda · as of 2026-05-13]
- Capital needs — Substantial additional capital may be needed; no guarantee of financing availability [sec_mda · as of 2026-03-25]
- Clinical trial setbacks — No assurance of clinical trial success or regulatory approval even after promising early results [sec_mda · as of 2026-03-25]
- Negative cash flows — Company has negative net cash flows from operating activities and expects net losses for several years [sec_mda · as of 2026-03-25]
What to watch
- Cash runway and ability to raise additional capital, given the company's negative cash flows and net losses [sec_mda · as of 2026-03-25]
- Progress of C1 platform collaborations and licensing deals, especially with global health organizations and CDMOs [sec_mda · as of 2026-03-25]
- Clinical development outcomes for C1-based vaccine candidates, such as H5 Avian Influenza and Mpox programs [sec_mda · as of 2025-11-12]
- Management's evaluation of going concern status and any subsequent actions [sec_mda · as of 2026-05-13]
Sources: SEC MD&A · Generated September 28, 2026 · How we verify sources →
Run DYADIC INTERNATIONAL INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DYADIC INTERNATIONAL INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$2M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.5%
- Days to cover
- 1.2
- Shares short
- 130,008
- Daily short volume (Oct 12, 2026)
- 48.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DYAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for DYADIC INTERNATIONAL INC?
DYADIC International Inc. (DYAI) is a biotechnology company developing microbial protein production platforms, primarily the C1 and Dapibus™ systems, for use in human and animal biopharmaceuticals and non-therapeutic products, while currently generating minimal revenue and facing significant financial challenges.
Who is the CEO of DYADIC INTERNATIONAL INC?
Mr. Mark A. Emalfarb is the chief executive officer of DYADIC INTERNATIONAL INC (DYAI).
Where is DYADIC INTERNATIONAL INC headquartered?
DYADIC INTERNATIONAL INC (DYAI) is headquartered in Jupiter, FL, United States.
What therapeutic areas does DYADIC INTERNATIONAL INC focus on?
DYADIC INTERNATIONAL INC develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.